V-01D-351 / Livzon Pharma - LARVOL DELTA

The Bivalent COVID-19 Booster Immunization after Three Doses of Inactivated Vaccine Augments the Neutralizing Antibody Response against Circulating Omicron Sublineages. (PubMed, J Clin Med) - P1 | "The bivalent V-01D-351 and BV-01-B5 and prototype V-01 booster demonstrated remarkable cross-reactive immunogenicity against the prototype and multiple emerging variants of concern (VOCs), with the geometric mean ratio (versus CoronaVac) in particular being 31.3 (500 vs. 16), 12.0 (192 vs. 16) and 8.5 (136 vs.16) against BA.4/5 14 days after the booster, respectively. Taken together, the modified bivalent-formulation V-01 boosters induced robust neutralizing responses against multiple Omicron sublineages, better than V-01 and remarkably superior to ICV booster, without compromising the safety and tolerability."

Journal • Infectious Disease • Novel Coronavirus Disease

COVID-19: Exploratory Clinical Study to Evaluation of the Safety and Immunogenicity of Bivalent Vaccine V-01D-351 (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: Livzon Pharmaceutical Group Inc.

New P1 trial • Infectious Disease • Novel Coronavirus Disease